查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年高通量筛选市场预测：按产品、技术、应用、最终用户和地区分類的全球分析
市场调查报告书
商品编码
1383355

到 2030 年高通量筛选市场预测：按产品、技术、应用、最终用户和地区分類的全球分析

High Throughput Screening Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球高通量筛选市场规模将达257亿美元，预计2030年将达到627.5亿美元，预测期内复合年增长率为13.6%。

生物技术、製药和生命科学研究的关键一步是高通量筛选 (HTS)。为了了解哪些化学物质具有活性或它们如何影响生物系统，我们需要快速测试大量化学和生物分子。此外，HTS 利用自动化机器人系统在相对较短的时间内处理数千至数百万个样本。药物研发在很大程度上依赖这项技术来帮助识别潜在的候选药物、研究与生物标的的相互作用以及评估安全性和有效性。

美国国会预算办公室公布的资料证实，2020年全球整体製药业研发支出近2,000亿美元，而2019年为8,300万美元。

药物开发和药物研发

现代药物研发发现和开发配合措施建立在高温超导的基础上。製药业一直在寻求创新药物来治疗从癌症到罕见遗传性疾病等各种疾病。此外，可以使用 HTS 快速筛选数千种化合物，以找到有前途的候选药物，从而显着加速并降低与药物开发过程相关的成本。

初期成本大

高温超导技术和系统的初期成本很高。先进的检测技术、机器人技术和高通量筛选设备的成本可能令人望而却步，特别是对于新兴企业、小型研究机构和学术机构。此外，通常需要外部资金筹措和合作研究来支付这些初期成本。

整合人工智慧和机器学习

机器学习和人工智慧 (AI) 的整合可能会彻底改变 HTS 程式。这些技术可以预测化合物行为、分析大资料集并增强筛选程序。此外，透过使用人工智慧主导的演算法，可以显着提高药物研发的效率和经济性，这些演算法可以显着改善命中识别、先导化合物优化和化合物优先排序。

缺乏经济透明度

HTS 市场可能会受到经济衰退、景气衰退和研究经费转移的重大影响。由于製药业和学术界的资金减少，高温超导研究和开发可能会放缓，从而限制最尖端科技的投资和创新。此外，长期计划可能会落空，而获得必要资源的机会可能会因金融不稳定而受到阻碍。

COVID-19 的影响：

高通量筛检 (HTS) 市场受到 COVID-19大流行的各种影响。儘管供应链中断、实验室关闭和资源缺乏最初减缓了研究和开发工作，但对快速药物研发发现和疫苗开发的需求导致了该病毒潜在治疗方法的开发。已经大大加速了。这增加了 HTS 市场对疫苗开发、病毒生物学研究以及抗病毒化合物筛选的需求。此外，这场大流行凸显了自动化和远端可控高温超导系统的重要性，它使研究人员能够在遵守安全预防措施和社交距离的同时进行研究。

基于细胞的检测领域预计将成为预测期内最大的领域

在高通量筛选（HTS）市场中，基于细胞的检测占据最大的市场占有率。基于细胞的检测对于药物研发和研究至关重要，它使用活细胞来检查对各种物质的反应。除了促进在更俱生物学相关性的背景下筛选化合物之外，它还提供了有关候选治疗药物的毒性和功效的深刻资讯。此外，基于细胞的检测是HTS市场的支柱，占据了很大一部分市场占有率，并且具有广泛的应用，包括药物筛选、毒性测试和目标识别。 HTS 在识别潜在的治疗方法候选者和了解疾病背后的复杂机制方面发挥特殊作用。

药物研发领域预计在预测期内复合年增长率最高

在高通量筛选（HTS）市场中，药物研发领域的复合年增长率最高。对各种病理的新药和治疗方法的需求不断增长是 HTS 市场成长的主要驱动力。药物研发涉及先导化合物的最佳化和潜在候选药物的鑑定，主要依靠高温超导技术进行快速有效的筛选。此外，自动化、机器人技术和资料分析的进步所带来的药物研发过程的简化正在加速新药的开发。

比例最高的地区：

高通量筛选（HTS）市场预计将占据北美地区的最大份额。这一优势被认为是由于对研发的大量投资、成熟的药物研发和生物技术行业以及对尖端药物发现和开发技术的强烈需求。顶级高温超导设备製造商和研究机构的存在以及政府的支持措施和资金进一步增强了北美作为高温超导市场主要企业的地位。此外，由于其强大的医疗保健系统和对精准医疗的关注，北美在 HTS 技术的使用方面处于世界领先地位。

复合年增长率最高的地区：

在高通量筛选 (HTS) 市场中，亚太地区的复合年增长率最高。这种快速成长的推动因素是中国和印度等国家对精准医疗的日益关注以及对生物技术和药物研究的投资增加。由于其庞大且多样化的患者群体以及具有成本效益的研发能力，该地区吸引了临床试验和药物研发倡议。此外，不断增加的生命科学研究和政府支持也对亚太高温超导市场的显着扩张发挥了关键作用，证实该地区是全球高温超导市场成长的关键引擎。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球高通量筛选市场：依产品

  • 介绍
  • 消耗品
    • 试剂和检测套件
    • 实验室设备
  • 乐器
    • 液体处理系统
    • 检测系统
    • 其他乐器
  • 服务
  • 软体
  • 其他产品

第6章全球高通量筛选市场：依技术分类

  • 介绍
  • 基于细胞的检测
    • 二维细胞培养
    • 3D细胞培养
      • 基于支架的技术
      • 水凝胶
      • 动物源性水凝胶
      • 基质胶
      • 胶原蛋白
      • 合成水凝胶
      • 藻酸盐/琼脂糖
      • 惰性基质/固体支架
      • 精细图案表面
      • 不需要鹰架的技术
      • 超低结合板
      • 悬滴板
      • 其他无支架技术
    • 基于报告基因的检测
    • 灌流细胞培养
  • 片晶载技术 (LOC)
  • 无标定技术
  • 超高通量筛选
  • 其他技术

第7章全球高通量筛选市场：依应用分类

  • 介绍
  • 药物研发
  • 生化筛检
  • 生命科学研究
  • 其他用途

第8章全球高通量筛选市场：依最终用户分类

  • 介绍
  • 製药和生物技术公司
  • 学术研究所
  • 受託研究机构（CRO）
  • 其他最终用户

第9章全球高通量筛选市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • GE Healthcare
  • Danaher Corporation
  • Agilent Technologies Inc
  • Tecan Group Ltd.
  • Corning Incorporated
  • Sigma-Aldrich Corporation
  • Charles River Laboratories International, Inc
  • Axxam SpA
  • Thermo Fisher Scientific, Inc.
  • Hamilton Company
  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Promega Corporation
  • BioTek Instruments, Inc.
  • PerkinElmer Inc.
  • Luminex Corporation
  • Aurora Biomed Inc
  • NanoTemper Technologies GmbH
  • Beckman Coulter Inc.
  • DIANA Biotechnologies, sro
Product Code: SMRC24205

According to Stratistics MRC, the Global High Throughput Screening Market is accounted for $25.70 billion in 2023 and is expected to reach $62.75 billion by 2030 growing at a CAGR of 13.6% during the forecast period. A crucial procedure in biotechnology, pharmaceutical, and life sciences research is high-throughput screening, or HTS. In order to determine which chemicals are active or to learn more about how they affect biological systems, a vast number of chemical or biological molecules must be rapidly tested. Furthermore, HTS processes thousands, even millions, of samples in a comparatively short amount of time by utilizing automated and robotic systems. Drug discovery relies heavily on this technology, which aids in the identification of possible drug candidates, the investigation of their interactions with biological targets, and the evaluation of their safety and effectiveness.

According to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries have spent nearly USD 200 billion on research and development in 2020 globally compared to USD 83 million in 2019.

Market Dynamics:

Driver:

Drug development and discovery

Modern drug discovery and development efforts are built on the foundation of HTS. Innovative medications are always being sought after by the pharmaceutical industry to treat a variety of illnesses, from cancer to uncommon genetic conditions. Moreover, thousands of compounds can be quickly screened with HTS to find promising drug candidates, greatly accelerating and cutting costs associated with the drug development process.

Restraint:

Large initial expenses

HTS technologies and systems require large upfront costs. For startups, smaller research organizations, and academic institutions in particular, the cost of advanced assay technologies, robotics, and high-throughput screening equipment can be prohibitive. Additionally, external funding or collaborations are frequently required to cover these upfront costs.

Opportunity:

Integration of AI and machine learning

HTS procedures could undergo a revolution if machine learning and artificial intelligence (AI) are integrated. These technologies can predict the behavior of compounds, analyze large datasets, and enhance screening procedures. Furthermore, the efficiency and financial viability of drug discovery can be greatly increased by using AI-driven algorithms to greatly improve hit identification, lead optimization, and compound prioritization.

Threat:

Lack of economic clarity

The HTS market may be significantly impacted by recessions, downturns in the economy, or shifts in research funding. HTS research and development may slow down as a result of reduced funding from both the pharmaceutical industry and academia, which would limit investment in and innovation from cutting-edge technologies. Moreover, long-term projects can be derailed, and access to necessary resources can be impeded by economic instability.

COVID-19 Impact:

The high-throughput screening (HTS) market was impacted by the COVID-19 pandemic in a number of ways. The need for quick drug discovery and vaccine development greatly accelerated the adoption of HTS technologies to screen and identify possible treatments for the virus, even though supply chain disruptions, laboratory closures, and resource shortages initially slowed down research and development activities. This led to an increase in demand for vaccine development, biological research on the virus, and screening of antiviral compounds in the HTS market. Furthermore, the pandemic highlighted the significance of automated and remote-capable HTS systems, enabling researchers to carry out their work while abiding by safety precautions and social distancing.

The Cell-based Assays segment is expected to be the largest during the forecast period

In the high-throughput screening (HTS) market, cell-based assays hold the largest market share. A vital part of drug discovery and research, cell-based assays use living cells to examine their reactions to different substances. In addition to facilitating the screening of compounds in more biologically relevant contexts, they offer insightful information about the possible toxicity and efficacy of therapeutic candidates. Moreover, cell-based assays are fundamental to the HTS market, accounting for a sizeable portion of the market share, and have a wide range of applications, such as drug screening, toxicity testing, and target identification. They play a special role in figuring out possible treatment candidates and comprehending the intricate mechanisms underlying diseases.

The Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the high-throughput screening (HTS) market, drug discovery is the segment with the highest CAGR. The rising demand for novel medications and treatments across a range of disease states is a major driver of market growth for HTS. Drug discovery, which includes optimizing lead compounds and identifying possible drug candidates, mainly depends on HTS technologies for quick and effective screening. Additionally, the development of new drugs has accelerated due to the streamlining of drug discovery processes brought about by advances in automation, robotics, and data analysis.

Region with largest share:

The high-throughput screening (HTS) market is anticipated to hold the largest share in the North American region. Significant investments in research and development, a well-established pharmaceutical and biotechnology industry, and a strong need for cutting-edge drug discovery and development technologies are all considered contributing factors to this dominance. Further bolstering North America's standing as a major player in the HTS market is the existence of top HTS equipment manufacturers and research facilities, as well as supportive government initiatives and funding. Furthermore, North America leads the world in the use of HTS technologies due to the region's strong healthcare system and emphasis on precision medicine.

Region with highest CAGR:

In the high-throughput screening (HTS) market, the Asia-Pacific region is growing at the highest CAGR. The growing emphasis on precision medicine in nations like China and India, as well as increased investments in biotechnology and pharmaceutical research, are driving this rapid growth. Clinical trials and drug discovery initiatives find the region appealing due to its large and diverse patient population and cost-effective research and development capabilities. Moreover, a rise in life sciences research endeavors and government backing also play a significant role in the impressive expansion of the Asia-Pacific HTS market, securing the region's standing as a major engine of global HTS market growth.

Key players in the market

Some of the key players in High Throughput Screening market include: GE Healthcare, Danaher Corporation, Agilent Technologies Inc, Tecan Group Ltd., Corning Incorporated, Sigma-Aldrich Corporation, Charles River Laboratories International, Inc, Axxam SpA, Thermo Fisher Scientific, Inc., Hamilton Company, Bio-Rad Laboratories, Inc, Merck KGaA, Promega Corporation, BioTek Instruments, Inc., PerkinElmer Inc., Luminex Corporation , Aurora Biomed Inc, NanoTemper Technologies GmbH, Beckman Coulter Inc. and DIANA Biotechnologies, s.r.o.

Key Developments:

In October 2023, GE HealthCare announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based Company, to develop, manufacture and commercialize SOFIE's Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Financial terms were not disclosed.

In August 2023, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash. Danaher plans to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.

In March 2023, Agilent Technologies Inc announced a multi-year distribution agreement with Proscia® - a leader in digital pathology - to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq® Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes.

Products Covered:

  • Consumables
  • Instruments
  • Services
  • Software
  • Other Products

Technologies Covered:

  • Cell-based Assays
  • Lab-on-a-Chip Technology (LOC)
  • Label-free Technology
  • Ultra High Throughput Screening
  • Other Technologies

Applications Covered:

  • Drug Discovery
  • Biochemical Screening
  • Life Sciences Research
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global High Throughput Screening Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
    • 5.2.1 Reagents & Assay Kits
    • 5.2.2 Laboratory Equipment
  • 5.3 Instruments
    • 5.3.1 Liquid Handling Systems
    • 5.3.2 Detection Systems
    • 5.3.3 Other Instruments
  • 5.4 Services
  • 5.5 Software
  • 5.6 Other Products

6 Global High Throughput Screening Market, By Technology

  • 6.1 Introduction
  • 6.2 Cell-based Assays
    • 6.2.1 2D Cell Culture
    • 6.2.2 3D Cell Culture
      • 6.2.2.1 Scaffold-based Technology
      • 6.2.2.2 Hydrogels
      • 6.2.2.3 Animal-derived Hydrogels
      • 6.2.2.4 Matrigel
      • 6.2.2.5 Collagen
      • 6.2.2.6 Synthetic Hydrogels
      • 6.2.2.7 Alginate/Agarose
      • 6.2.2.8 Inert Matrix/Solid Scaffolds
      • 6.2.2.9 Micropatterned Surfaces
      • 6.2.2.10 Scaffold-free Technology
      • 6.2.2.11 Ultra-low Binding Plates
      • 6.2.2.12 Hanging-drop Plates
      • 6.2.2.13 Other Scaffold-free Technologies
    • 6.2.3 Reporter-based Assays
    • 6.2.4 Perfusion Cell Culture
  • 6.3 Lab-on-a-Chip Technology (LOC)
  • 6.4 Label-free Technology
  • 6.5 Ultra High Throughput Screening
  • 6.6 Other Technologies

7 Global High Throughput Screening Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Discovery
  • 7.3 Biochemical Screening
  • 7.4 Life Sciences Research
  • 7.5 Other Applications

8 Global High Throughput Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Academic & Research Institutes
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Other End Users

9 Global High Throughput Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GE Healthcare
  • 11.2 Danaher Corporation
  • 11.3 Agilent Technologies Inc
  • 11.4 Tecan Group Ltd.
  • 11.5 Corning Incorporated
  • 11.6 Sigma-Aldrich Corporation
  • 11.7 Charles River Laboratories International, Inc
  • 11.8 Axxam SpA
  • 11.9 Thermo Fisher Scientific, Inc.
  • 11.10 Hamilton Company
  • 11.11 Bio-Rad Laboratories, Inc
  • 11.12 Merck KGaA
  • 11.13 Promega Corporation
  • 11.14 BioTek Instruments, Inc.
  • 11.15 PerkinElmer Inc.
  • 11.16 Luminex Corporation
  • 11.17 Aurora Biomed Inc
  • 11.18 NanoTemper Technologies GmbH
  • 11.19 Beckman Coulter Inc.
  • 11.20 DIANA Biotechnologies, s.r.o.

List of Tables

  • Table 1 Global High Throughput Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global High Throughput Screening Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global High Throughput Screening Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 4 Global High Throughput Screening Market Outlook, By Reagents & Assay Kits (2021-2030) ($MN)
  • Table 5 Global High Throughput Screening Market Outlook, By Laboratory Equipment (2021-2030) ($MN)
  • Table 6 Global High Throughput Screening Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 7 Global High Throughput Screening Market Outlook, By Liquid Handling Systems (2021-2030) ($MN)
  • Table 8 Global High Throughput Screening Market Outlook, By Detection Systems (2021-2030) ($MN)
  • Table 9 Global High Throughput Screening Market Outlook, By Other Instruments (2021-2030) ($MN)
  • Table 10 Global High Throughput Screening Market Outlook, By Services (2021-2030) ($MN)
  • Table 11 Global High Throughput Screening Market Outlook, By Software (2021-2030) ($MN)
  • Table 12 Global High Throughput Screening Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 13 Global High Throughput Screening Market Outlook, By Technology (2021-2030) ($MN)
  • Table 14 Global High Throughput Screening Market Outlook, By Cell-based Assays (2021-2030) ($MN)
  • Table 15 Global High Throughput Screening Market Outlook, By 2D Cell Culture (2021-2030) ($MN)
  • Table 16 Global High Throughput Screening Market Outlook, By 3D Cell Culture (2021-2030) ($MN)
  • Table 17 Global High Throughput Screening Market Outlook, By Reporter-based Assays (2021-2030) ($MN)
  • Table 18 Global High Throughput Screening Market Outlook, By Perfusion Cell Culture (2021-2030) ($MN)
  • Table 19 Global High Throughput Screening Market Outlook, By Lab-on-a-Chip Technology (LOC) (2021-2030) ($MN)
  • Table 20 Global High Throughput Screening Market Outlook, By Label-free Technology (2021-2030) ($MN)
  • Table 21 Global High Throughput Screening Market Outlook, By Ultra High Throughput Screening (2021-2030) ($MN)
  • Table 22 Global High Throughput Screening Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 23 Global High Throughput Screening Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global High Throughput Screening Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 25 Global High Throughput Screening Market Outlook, By Biochemical Screening (2021-2030) ($MN)
  • Table 26 Global High Throughput Screening Market Outlook, By Life Sciences Research (2021-2030) ($MN)
  • Table 27 Global High Throughput Screening Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global High Throughput Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global High Throughput Screening Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 30 Global High Throughput Screening Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 31 Global High Throughput Screening Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 32 Global High Throughput Screening Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.